Effectiveness of school-based preventive chemotherapy strategies for sustaining the control of schistosomiasis in Côte d'Ivoire: Results of a 5-year cluster randomized trial.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
15
01
2020
accepted:
30
09
2020
entrez:
15
1
2021
pubmed:
16
1
2021
medline:
18
5
2021
Statut:
epublish
Résumé
Preventive chemotherapy using praziquantel is the mainstay for schistosomiasis control. However, there is little evidence on what is supposed to be the most effective school-based treatment strategy to sustain morbidity control. The aim of this study was to compare differences in Schistosoma mansoni prevalence and infection intensity between three different schedules of school-based preventive chemotherapy in an area with moderate prevalence of S. mansoni in Côte d'Ivoire. Seventy-five schools were randomly assigned to one of three intervention arms: (i) annual school-based preventive chemotherapy with praziquantel (40 mg/kg) over four years; (ii) praziquantel treatment only in the first two years, followed by two years whithout treatment; and (iii) praziquantel treatment in years 1 and 3 without treatment in-between. Cross-sectional parasitologic surveys were carried out prior to each round of preventive chemotherapy. The difference in S. mansoni prevalence and infection intensity was assessed by multiple Kato-Katz thick smears, among children aged 9-12 years at the time of each survey. First-grade children, aged 5-8 years who had never received praziquantel, were also tested at baseline and at the end of the study. Overall, 7,410 children aged 9-12 years were examined at baseline and 7,223 at the final survey. The baseline prevalence of S. mansoni was 17.4%, 20.2%, and 25.2% in arms 1, 2, and 3, respectively. In the final year, we observed the lowest prevalence of 10.4% in arm 1, compared to 18.2% in arm 2 and 17.5% in arm 3. The comparison between arms 1 and 2 estimated an odds ratio (OR) of 0.52 but the difference was not statistically significant (95% confidence interval (CI) = 0.23-1.16). Likewise the difference between arms 1 and 3 lacked statistical significance (OR = 0.55, 95% CI = 0.23-1.29). There was no noteworthy difference observed between arms 2 and 3 (OR = 1.06, 95% CI = 0.64-1.75). The lowest S. mansoni fecal egg counts in the final year survey were observed in arm 1 (7.9 eggs per gram of stool (EPG)). However, compared with 11.5 EPG in arm 2 and 15.4 EPG in arm 3, the difference lacked statistical significance. There were 4,812 first-grade children examined at baseline and 4,513 in the final survey. The overall prevalence of S. mansoni in these children slightly decreased in arms 1 (from 4.5% to 3.6%) and 2 (from 4.7% to 4.3%), but increased in arm 3 (from 6.8% to 7.9%). However, there was no significant difference in prevalence and infection intensity observed between study arms. The three treatment schedules investigated led to a reduction in the prevalence and intensity of S. mansoni infection among children aged 9-12 years. Comparing intervention arms at the end of the study, no statistically significant differences were observed between annual treatement and the other two treatment schedules, neither in reduction of prevalence nor intensity of infection. It is important to combine our results with those of three sister trials conducted simultaneously in other African countries, before final recommendations can be drawn.
Sections du résumé
BACKGROUND
Preventive chemotherapy using praziquantel is the mainstay for schistosomiasis control. However, there is little evidence on what is supposed to be the most effective school-based treatment strategy to sustain morbidity control. The aim of this study was to compare differences in Schistosoma mansoni prevalence and infection intensity between three different schedules of school-based preventive chemotherapy in an area with moderate prevalence of S. mansoni in Côte d'Ivoire.
METHODOLOGY
Seventy-five schools were randomly assigned to one of three intervention arms: (i) annual school-based preventive chemotherapy with praziquantel (40 mg/kg) over four years; (ii) praziquantel treatment only in the first two years, followed by two years whithout treatment; and (iii) praziquantel treatment in years 1 and 3 without treatment in-between. Cross-sectional parasitologic surveys were carried out prior to each round of preventive chemotherapy. The difference in S. mansoni prevalence and infection intensity was assessed by multiple Kato-Katz thick smears, among children aged 9-12 years at the time of each survey. First-grade children, aged 5-8 years who had never received praziquantel, were also tested at baseline and at the end of the study.
PRINCIPAL FINDINGS
Overall, 7,410 children aged 9-12 years were examined at baseline and 7,223 at the final survey. The baseline prevalence of S. mansoni was 17.4%, 20.2%, and 25.2% in arms 1, 2, and 3, respectively. In the final year, we observed the lowest prevalence of 10.4% in arm 1, compared to 18.2% in arm 2 and 17.5% in arm 3. The comparison between arms 1 and 2 estimated an odds ratio (OR) of 0.52 but the difference was not statistically significant (95% confidence interval (CI) = 0.23-1.16). Likewise the difference between arms 1 and 3 lacked statistical significance (OR = 0.55, 95% CI = 0.23-1.29). There was no noteworthy difference observed between arms 2 and 3 (OR = 1.06, 95% CI = 0.64-1.75). The lowest S. mansoni fecal egg counts in the final year survey were observed in arm 1 (7.9 eggs per gram of stool (EPG)). However, compared with 11.5 EPG in arm 2 and 15.4 EPG in arm 3, the difference lacked statistical significance. There were 4,812 first-grade children examined at baseline and 4,513 in the final survey. The overall prevalence of S. mansoni in these children slightly decreased in arms 1 (from 4.5% to 3.6%) and 2 (from 4.7% to 4.3%), but increased in arm 3 (from 6.8% to 7.9%). However, there was no significant difference in prevalence and infection intensity observed between study arms.
CONCLUSIONS/SIGNIFICANCE
The three treatment schedules investigated led to a reduction in the prevalence and intensity of S. mansoni infection among children aged 9-12 years. Comparing intervention arms at the end of the study, no statistically significant differences were observed between annual treatement and the other two treatment schedules, neither in reduction of prevalence nor intensity of infection. It is important to combine our results with those of three sister trials conducted simultaneously in other African countries, before final recommendations can be drawn.
Identifiants
pubmed: 33449924
doi: 10.1371/journal.pntd.0008845
pii: PNTD-D-20-00081
pmc: PMC7810315
doi:
Substances chimiques
Praziquantel
6490C9U457
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0008845Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Clin Microbiol Infect. 2015 Jun;21(6):529-42
pubmed: 25843503
PLoS Negl Trop Dis. 2017 Dec 8;11(12):e0006061
pubmed: 29220347
Wkly Epidemiol Rec. 2017 Dec 08;92(49):749-60
pubmed: 29218962
Am J Trop Med Hyg. 2016 Feb;94(2):352-60
pubmed: 26598571
PLoS Negl Trop Dis. 2010 Dec 21;4(12):e910
pubmed: 21200423
Lancet. 2014 Jun 28;383(9936):2253-64
pubmed: 24698483
Am J Trop Med Hyg. 2018 Dec;99(6):1573-1579
pubmed: 30350779
PLoS Negl Trop Dis. 2009 Sep 08;3(9):e513
pubmed: 19907632
Nature. 2011 Jun 29;474(7353):569-71
pubmed: 21720345
Parasit Vectors. 2020 Jul 2;13(1):337
pubmed: 32616074
World Health Organ Tech Rep Ser. 2002;912:i-vi, 1-57, back cover
pubmed: 12592987
Lancet Glob Health. 2019 Aug;7(8):e1118-e1129
pubmed: 31255591
Am J Trop Med Hyg. 2017 Dec;97(6):1810-1817
pubmed: 29016344
Lancet Infect Dis. 2015 Aug;15(8):927-40
pubmed: 26004859
Parasit Vectors. 2015 Feb 05;8:82
pubmed: 25652120
PLoS Negl Trop Dis. 2017 Apr 20;11(4):e0005517
pubmed: 28426653
PLoS Negl Trop Dis. 2016 Jan 20;10(1):e0004329
pubmed: 26789749
Trop Med Health. 2014 Jun;42(2 Suppl):25-32
pubmed: 25425948
Trop Med Int Health. 2005 Jan;10(1):42-57
pubmed: 15655013
J Infect Dis. 2017 Dec 12;216(11):1425-1433
pubmed: 28968877
Acta Trop. 2013 Nov;128(2):423-40
pubmed: 22580511
BMC Public Health. 2014 Dec 17;14:1290
pubmed: 25519880
PLoS Negl Trop Dis. 2017 Oct 23;11(10):e0006033
pubmed: 29059190
Nat Rev Dis Primers. 2018 Aug 9;4(1):13
pubmed: 30093684
BMC Infect Dis. 2016 May 26;16:229
pubmed: 27230666
Int J Parasitol. 2016 Jun;46(7):439-45
pubmed: 26940547
Am J Trop Med Hyg. 2019 Sep;101(3):617-627
pubmed: 31287046
Am J Trop Med Hyg. 2020 Jul;103(1_Suppl):14-23
pubmed: 32400356
PLoS Negl Trop Dis. 2011 Apr 12;5(4):e1036
pubmed: 21532740